Mainz Biomed Announces Stock Split
November 29, 2024 08:45 ET
|
Mainz BioMed NV
Mainz Biomed Announces Stock Split
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
November 12, 2024 09:00 ET
|
Mainz BioMed NV
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
October 21, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
October 08, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
October 01, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
September 18, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
September 04, 2024 04:01 ET
|
Mainz BioMed NV
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of AI for the Expansion and Optimization of Biomarker Selection for PancAlert
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
July 25, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
July 09, 2024 03:01 ET
|
Mainz BioMed NV
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Provides Half Year 2024 Corporate Update
July 02, 2024 08:01 ET
|
Mainz BioMed NV
Mainz Biomed Provides Half Year 2024 Corporate Update -
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study